The Conundrum of Platelet P2Y&lt;sub&gt;12&lt;/sub&gt; Inhibition in ST-Segment Elevation Myocardial Infarction

Antithrombotic therapy, including antiplatelet and anticoagulant agents, is the cornerstone of pharmacological treatment to optimize clinical outcomes in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). Intravenous anticoagulant drugs available for PPCI include the indirect thrombin inhibitors unfractionated heparin and low-molecular-weight heparin, and the direct thrombin inhibitor bivalirudin. Intravenous antiplatelet drugs mainly include glycoprotein IIb/IIIa inhibitors and the P2Y-receptor inhibitor cangrelor. Dual antiplatelet therapy with aspirin and an oral P2Y-receptor inhibitor is pivotal for the acute and long-term treatment of patients with STEMI undergoing PPCI. Prasugrel and ticagrelor provide a more prompt, potent, and predictable antiplatelet effect compared with clopidogrel, which translates into better clinical outcomes. Therefore, these agents are the first-line treatment in PPCI. However, patients can still experience adverse ischaemic events, which might be in part attributed to alternative pathways triggering thrombosis. Thrombin has an important role, suggesting the need for strategies directly targeting circulating thrombin or other factors of the coagulation cascade, such as oral anticoagulants (rivaroxaban), and the thrombin receptor on the platelet membrane (vorapaxar). In this Review, we provide an overview of currently available antithrombotic therapies used in patients with STEMI undergoing PPCI, results from pivotal clinical trials and their implications for guidelines, as well as recommendations for clinical practice.

show abstract

Antithrombotic therapy for patients with STEMI undergoing primary PCI

Franchi

Rollini

Angiolillo

2017

Nat Rev Cardiol

View full text Add to dashboard Cite

show abstract

Antithrombotic treatment in primary percutaneous coronary intervention

Voll

Kuna

Ndrepepa

et al. 2021

Expert Review of Cardiovascular Therapy

View full text Add to dashboard Cite

Crushed ticagrelor in comatose patients treated with primary percutaneous coronary intervention

Rollini¹,

Franchi²,

Angiolillo³

2017

EuroIntervention

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

The Conundrum of Platelet P2Y<sub>12</sub> Inhibition in ST-Segment Elevation Myocardial Infarction

Cited by 3 publications

References 14 publications

Antithrombotic therapy for patients with STEMI undergoing primary PCI

Antithrombotic therapy for patients with STEMI undergoing primary PCI

Antithrombotic treatment in primary percutaneous coronary intervention

Crushed ticagrelor in comatose patients treated with primary percutaneous coronary intervention

Contact Info

Product

Resources

About